RB1 and cancer: Importantly, recent studies have shown that therapy-resistant cancers, in which RB1 inactivation most commonly occurs (10, 11, 13, 14), are vulnerable to ferroptosis (30, 31), and RB1 knockdown appears to enhance the sensitivity of liver cancer cells to sorafenib-induced ferroptosis in vitro (32).